Networking opportunity for previously funded projects in personalised medicine
Call Announcement & Networking Projects
The call documents of the EP PerMed NSC2025 were published in May 2025. The call is closed, but if you are interested in the original documents, you can read them here. The 13 funded networking projects can be found in the EP PerMed Project Database.
The European Partnership for Personalised Medicine (EP PerMed) Networking Support Call 2025 (NSC2025) represents a key instrument for fostering collaboration, knowledge exchange, and community building in personalised medicine (PM) across Europe and beyond. Complementing EP PerMed’s larger research funding schemes, the NSC2025 is specifically designed to stimulate the creation and consolidation of multidisciplinary networks that advance research, strategic dialogue, innovation pathways, and implementation-oriented discussions in personalised medicine.
With a total investment of €389,000, via the NSC2025 EP PerMed will fund 13 networking events with a diverse portfolio spanning multiple health categories and research domains. The supported networks bring together applicants from a wide geographical range, reflecting strong European and international participation. In total, 81 partners from 17 countries will be involved across the funded networks, demonstrating broad engagement of the personalised medicine community.
A distinctive feature of the NSC2025 is its strong emphasis on maximising the impact of previous ERA PerMed and EP PerMed investments by building on expertise and outcomes from previously funded consortia. Each funded network was required to involve at least two participants who are or have been partners in two different ERA PerMed or EP PerMed funded consortia. This requirement ensures continuity, maximises the impact of prior funding, and actively fosters inter-consortium collaboration and synergy. By connecting results, expertise, and communities across calls and thematic areas, the NSC2025 strengthens the coherence and long-term sustainability of the personalised medicine portfolio.
Through these networking activities, EP PerMed continues to build a dynamic, interconnected environment that accelerates the advancement and implementation of personalised medicine research in Europe and beyond.
Overall, the results of the NSC2025 reflect a portfolio of networking events that strengthen collaboration, continuity, and knowledge exchange within the personalised medicine community. The funded events address key health priorities, with a predominant focus on cancer and neoplasms, while also covering additional disease areas and cross-cutting health domains. The supported activities span the research and innovation pathway, particularly in detection, screening and diagnosis, development and evaluation of therapeutic interventions, and health and social care service research. The call demonstrates strong transnational engagement, with principal applicants from ten countries and co-applicants spanning seventeen countries, and the majority of networks exceeding the minimum eligibility requirements in terms of country participation. Importantly, NSC2025 builds on 27 previously funded ERA PerMed and EP PerMed projects across five call years (2018–2024), fostering inter-consortium collaboration and cross-network connectivity. Together, these features highlight NSC2025’s role in fostering collaboration and reinforcing connections across the European personalised medicine community.
NSC2025 Call Statistics: Key Insights
The networking events funded under the EP PerMed NSC2025 were classified according to the Health Research Classification System (HRCS) to analyse the main health categories addressed, as well as the primary research activities undertaken by the projects. More than half of the funded networks (7 out of 13) focus on cancer and neoplasms, while approximately 15% (2 out of 13) address generic health relevance. The remaining four health categories are each covered by one network event (figure 1).
Regarding the research activities of the funded networking events, five of them focus on detection, screening and diagnosis, four focus on development of treatments and therapeutic interventions, three concentrate on health and social care service research and one network focuses on evaluation of treatments and therapeutic interventions (figure 2).
EP PerMed NSC2025 funded networking events exemplify transnational collaboration, with principal applicants coming from 10 different countries and co-applicants spanning 17 different countries (as can be seen in figure 3).
Furthermore, the transnational aspect can also be seen in every funded network, since the majority of the networks (11 out of 13) have 4 or more countries involved (when the mandatory eligibility criteria was 3 countries) – see figure 4.
When looking at the funded networks’ composition (figure 5), it could be noted that the majority of the networks (n=8) include 6-8 partners (62%).
The overall distribution of the partners in the funded networks across sectors shows a strong representation of academia, which accounts for 65% of all partners, followed by the clinical and public health research sector at 25% (figure 6). In addition, four patient organisations and two for-profit private partners participate as applicants in the funded networks.
The sex distribution within NSC2025 funded networks is presented in figure 7, with female accounting for 23% of the principal applicants and 44% of co-applicants, and male for 77% and 56%, respectively (figure 7).
NSC2025 funded networks build on expertise from 27 previously funded ERA/EP PerMed projects across five call years (2018, 2019, 2020, 2022 and 2024 ). Most funded networks connect partners from two (n=9) or three (n=3) previously funded consortia, with one network bringing together expertise from eight earlier funded consortia. Seven previously funded consortia act as connectors across multiple NSC2025 networks, highlighting the emergence of an interconnected and collaborative PM environment.
As illustrated in Figure 8, the distribution of connections across call years shows that collaboration is not confined to a single funding generation. The strong representation of JTC2024 projects demonstrates early momentum and active engagement of newly funded consortia, while the continued involvement of projects from 2018–2020 highlights sustained impact beyond the original funding period. Several networks link projects from multiple call years, thus reinforcing continuity over time. Together, these patterns could indicate that knowledge and expertise developed through earlier calls continue to evolve and remain active.
